BLA 761183 · Provention Bio INC
Tzield
Teplizumab-Mzwv · Injection · CD3-directed Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Nov 17, 2022
Approved uses
3
Original approval plus efficacy supplements
Registered trials
19
4 Phase 3, 7 recruiting
FAERS reports
720
100 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: Viral Reactivation Serious, life-threatening cases of viral reactivation, including Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation have been reported with TZIELD. Patients who are immunocompromised are at increased risk. Serious cases have also been reported in adults with higher body surface area or comorbid conditions, such as adrenal insufficiency or cardiovascular disease. The majority of serious cases occurred in patients who continued TZIELD treatment despite persistent, severe lymphopenia. Severe lymphopenia may be prolonged in adults. ( 5.1 , 5.4 ) Test patients for active EBV and CMV infection prior to starting treatment. TZIELD is contraindicated in patients who are immunocompromised or have active viral infection (such as EBV or CMV infection). Adhere to lymphocyte count monitoring requirements and discontinuation recommendations. Monitor patients...
What it is approved for
From the label in effect Nov 6, 2026.
TZIELD is indicated to [see Dosage and Administration (2.1) ]: Delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D. Delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. This indication is approved under accelerated approval based on evidence of reduced C-peptide decline [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Limitations of Use: There is limited evidence of safety and effectiveness in patients aged 45 years and older with Stage 2 T1D. TZIELD is not effective as a disease modifying therapy in non-autoimmune dysglycemic conditions . TZIELD is a CD3-directed antibody indicated to: ( 1 ) Delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D. Delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. This indication is approved under accelerated approval based on evidence of reduced C-peptide decline. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Limitations of Use : ( 1 ) There is limited evidence of safety and effectiveness in patients aged 45 years and older with Stage 2 T1D. TZIELD is not effective as a disease modifying therapy in non-autoimmune dysglycemic conditions.
Mechanism: Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 T1D in adult and pediatric patients aged 1 year and older with Stage 2 T1D and delays the decline in endogenous insulin production in patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 12, 2026 Supplement 10 · Efficacy · priority review OrphanLetterReviewLabel
- Apr 20, 2026 Supplement 13 · Efficacy · priority review OrphanLetterLabel
- Nov 17, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterMedication Guide
1 products under this application
- TZIELD · TEPLIZUMAB-MZWV 2MG/2ML(1MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Teplizumab" as an intervention, any sponsor and status, largest first.
- A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07088068 · 723 participants (planned) · Start Aug 6, 2025 · Primary completion Jun 6, 2028
Drug: Teplizumab · For: Type 1 Diabetes Mellitus
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 201 sites in all
- The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusPivotal-lookingCompleted
MacroGenicsIndustry
NCT00385697 · 554 participants · Start Oct 2006 · Primary completion Jun 2010
Drug: Teplizumab; Placebo · For: Type 1 Diabetes Mellitus
Sites: Birmingham, Alabama; Jonesboro, Arkansas; Little Rock, Arkansas · 115 sites in all
- Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of TeplizumabPivotal-lookingCompleted
Provention Bio, Inc.Industry
NCT03875729 · 328 participants · Start Apr 5, 2019 · Primary completion May 1, 2023
Drug: teplizumab; Placebo · For: Type 1 Diabetes Mellitus
Sites: San Diego, California; San Francisco, California; Walnut Creek, California · 62 sites in all
- Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusPivotal-lookingTerminated
MacroGenicsIndustry
NCT00920582 · 254 participants · Start Sep 2009 · Primary completion Apr 2012
Drug: Teplizumab Herold Regimen; Placebo and 2 more · For: Type 1 Diabetes Mellitus
Sites: Birmingham, Alabama; Jonesboro, Arkansas; Little Rock, Arkansas · 118 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00129259 · 83 participants · Start Sep 2005 · Primary completion Mar 2011
Drug: Anti-CD3 mAb · For: Diabetes Mellitus, Type 1
Sites: San Francisco, California; Denver, Colorado; New Haven, Connecticut · 7 sites in all
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT01030861 · 76 participants · Start Aug 2010 · Primary completion Nov 2018
Drug: Teplizumab; Placebo infusion · For: Autoantibody Positive; Non-diabetic Relatives at Risk for Type 1 Diabetes; High Risk and 1 more
Sites: San Francisco, California; Stanford, California; Denver, Colorado · 19 sites in all
Yale UniversityAcademic, hospital or other
NCT00378508 · 63 participants · Start Sep 2006 · Primary completion Aug 2011
Drug: mAb hOKT3gamma1(Ala-Ala), Teplizumab; Placebo Arm · For: Type 1 Diabetes Mellitus
Sites: San Francisco, California; Aurora, Colorado; New Haven, Connecticut · 4 sites in all
- Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 DiabetesNot yet recruiting
Abdullah KarsAcademic, hospital or other
NCT07610213 · 60 participants (planned) · Start Jan 1, 2027 · Primary completion Dec 31, 2029
Drug: Teplizumab; Intralymphatic Insulin Immunotherapy (ILIT) · For: Type 1 Diabetes Mellitus (T1DM); Type 1 Diabetes Mellitus; Autoimmune Diabetes
Sites: Ankara, Turkey (Türkiye)
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash166
- nausea139
- pyrexia120
- fatigue119
- vomiting92
- headache86
- lymphopenia62
- lymphocyte count decreased55
- chills51
- rash pruritic44
- pain42
- pruritus41
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 78 |
| 2024 | 173 |
| 2025 | 205 |
| 2026 | 264 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Tzield (Teplizumab-Mzwv) · HCPCS J9381
2024 spending
$404K
Beneficiaries
n/a
29 claims
Per beneficiary
n/a
2024 ASP limit $36.62 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $403,715 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC, Bundy BN, Long SA, et al. · N Engl J Med 2019 · Clinical Trial, Phase II, Multicenter Study
- Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
Ramos EL, Dayan CM, Chatenoud L, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
Sims EK, Bundy BN, Stier K, et al. · Sci Transl Med 2021 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes.
Lledó-Delgado A, Preston-Hurlburt P, Currie S, et al. · J Clin Invest 2024 · Randomized Controlled Trial, Multicenter Study
- A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function in people newly diagnosed with type 1 diabetes: results from randomised controlled trials of immunomodulatory therapies.
Beese SE, Price MJ, Tomlinson C, et al. · BMC Med 2025 · Systematic Review, Network Meta-Analysis
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, et al. · Lancet 2011 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Provention Bio INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.